SCHEMBL8934730

SCHEMBL8934730

C=CCOc1ccc(-c2ccc(-c3ccc(C4CCC(COCCC)CC4)c(F)c3)cc2)c(F)c1F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.33
GABRB2 P47870 1/20 0.33
HTR2C P28335 8/20 0.32
HTR2B P41595 3/20 0.32
HTR2A P28223 6/20 0.32
FFAR4 Q5NUL3 3/20 0.31
DGAT1 O75907 1/20 0.31
ALOX5AP P20292 1/20 0.30
FEN1 P39748 1/20 0.30
ADRB2 P07550 1/20 0.30
HTR1A P08908 1/20 0.30
CHRM5 P08912 1/20 0.30
ADRA2A P08913 1/20 0.30
DRD2 P14416 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
DRD4 P21917 1/20 0.30
HRH2 P25021 1/20 0.30
SLC6A4 P31645 1/20 0.30
HTR7 P34969 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8933980 0.89 HTR2C (0.34) HTR2CHTR2BHTR2AFFAR4DGAT1
SCHEMBL8960227 0.86 HTR2C (0.33) HTR2CHTR2BHTR2AFFAR4DGAT1
SCHEMBL8934040 0.86 HTR2C (0.33) HTR2CHTR2BHTR2AFFAR4DGAT1
SCHEMBL15255877 0.85 HTR2C (0.35) GABRA1GABRB2HTR2CHTR2BHTR2A
SCHEMBL8934786 0.85 HTR2C (0.36) HTR2CHTR2BHTR2AFFAR4ALOX5AP
SCHEMBL8960692 0.84 HTR2C (0.32) HTR2CHTR2BHTR2AFFAR4DGAT1
SCHEMBL8934719 0.84 FFAR4 (0.37) HTR2CHTR2BHTR2AFFAR4DGAT1
SCHEMBL8934335 0.84 HTR2C (0.35) HTR2CHTR2BHTR2AFFAR4ADRB2
SCHEMBL8934690 0.84 GABRA1 (0.37) GABRA1GABRB2FFAR4DGAT1
SCHEMBL8961138 0.83 HTR2C (0.31) HTR2CHTR2BHTR2AFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8187494-B2 Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-05-29 US disclosed
US-8187494-B2 Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device JNC CORPORATION (JP) 2012-05-29 US disclosed
US-20100309402-A1 FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2010-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100309402-A1 FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE KIF23, HCN3, FZD7 GABRA1 3442/4885GABRB2 3958/4885HTR2C 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.